Scribe priced a $128.7 million IPO, funding progress across its in vivo gene-silencing and lipid-targeting pipeline. The California biotech priced 8.58 million shares at $15.00 and also sold an additional 500,000 shares to Sanofi in a concurrent private placement. Scribe said proceeds will support the ongoing Phase 1 study of STX-1150, an epigenetic therapy intended to silence PCSK9 in the liver, and it plans to advance STX-1400 and preclinical work for STX-1200. The IPO also signals continued market appetite for differentiated gene modulation programs with partnered validation. For the broader biotech IPO window, the deal adds to a string of 2026 public-market entries focused on clinical execution rather than purely platform narratives.